Expectant parents could soon have another new option this fall to protect their newborns from RSV, the most common cause of hospitalization in American infants.
to the committee suggest it would not be cost effective to issue recommendations for giving both shots, which together were modeled to cost $700 for each child before insurance. Beyfortus would effectively be a backup, under their
, largely offered only to babies born to parents who did not get Abyrsvo during pregnancy or who are at higher risk of severe disease.Further complicating the new recommendations are a handful of very rare preterm births seen in babies of moms who received Abrysvo during pregnancy. While the number in Pfizer's trial was too small to be statistically significant, it came after a larger uptick in preterm births was big enough to force GSK to halt a separate RSV vaccine trial in pregnant women"We have had long discussions about whether or not there could, or is not, a biologic plausibility to this," the CDC's Katherine Fleming Dutra told the ACIP at aThis puzzled some on the FDA's vaccines panel earlier this year as well.
"I'm troubled, as everybody is, by the prematurity issue. And I'm not sure that running it through another maybe season is going to give us an answer. And I think we've heard that observational studies, as we go forward, will fairly quickly give us an answer if there is a problem there," Dr.
"The available data are insufficient to establish or exclude a causal relationship between preterm birth and Abrysvo," the agency said.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA approves 1st maternal RSV vaccine to help protect infantsThe U.S. Food and Drug Administration has approved the first maternal vaccine intended to help protect newborns against respiratory syncytial virus (RSV).
Read more »
US FDA approves Pfizer's maternal RSV vaccine to protect infantsThe U.S. Food and Drug Administration on Monday approved Pfizer's respiratory syncytial virus (RSV) vaccine for use in women during the middle of the third trimester of pregnancy to protect their babies.
Read more »
Flu, Covid and RSV: Preventing another 'Tripledemic'As summer nears its end and the school year begins, it's a good time to think about getting those fall vaccinations against viruses that circulate in colder weather. A so-called 'Tripledemic' of Covid-19, the flu and RSV spread throughout the country last winter. To prevent a repeat, health officials are encouraging everyone to get vaccinated against Covid-19 and the flu, and now there are new protections against RSV. CBS News Bay Area's Ryan Yamamoto asks Dr. Jorge Salinas, infectious diseases specialist at Stanford Health Care, about the recommended vaccines
Read more »
On Abortion Pills, Federal Appeals Court Prescribes Justice for FDAAmericans concerned about the safety, health, and welfare of women and girls in this country received welcome news last week.
Read more »
Regeneron shares climb after FDA approval of macular degeneration treatmentShares of Regeneron Pharmaceuticals Inc. gained 1.4% premarket on Monday after the company said late Friday that the U.S. Food and Drug Administration had...
Read more »